Frank Perabo, MD, PhD
Before ESSA, Dr. Perabo was Executive Director at Astellas Pharma Inc., Oncology Global Development, where he was instrumental in the development and worldwide approval of XTANDI® (Enzalutamide). Before that, he worked as Global Medical Lead in multiple preclinical and early clinical to Phase 3 development programs; successfully directing various projects at Astellas Europe including Myrbetriq®/BetmigaTM (Mirabegron) and VesomniTM. Previously, he co-founded a consulting company for early phase oncology drug development, and was member of a Management team at an Oncology Start-up CRO. Dr. Perabo has extensive experience with start-up companies, successfully translating academic research into clinical programs, as well as licensing activities. He obtained his medical training at the University of Munich, with clinical training in surgery and urology in Munich, Freiburg and Bonn after graduating magna cum laude . He obtained a PhD for his work on ‘signal transduction pathways’ in cancer biology from the University of Munich. He is a European board-certified urologist, and an Associate Professor at Bonn University, and member of several urologic and oncologic associations. Dr. Perabo has received multiple international awards in urology and oncology research.
Vlad Vitoc, MD, MBA
His experience includes managing and supporting over 20 early, launch, and mature stage compounds, amongst which targeted therapies and immune therapies, across more than 25 tumor types – amongst which colorectal cancer, hepatocellular carcinoma, lung cancer, breast cancer prostate cancer, renal cell carcinoma. In his previous role at Barricade Therapeutics, he served as the Chief Business Officer and SVP Medical Affairs, leading the capitalization efforts and the pharmaceutical business development activities. At Puma Biotechnology, he served as VP Medical Affairs and built the Medical organization supporting the launch of NERLYNX (neratinib) in extended adjuvant breast cancer. Before Puma, Dr. Vitoc was the Executive Medical Director for pipeline products at Incyte Corporation, establishing the medical affairs support for compounds transitioning from preclinical to phase I and II clinical trials. Before that, he was Sr Medical Director at Astellas Pharma Inc., supporting the launch and development of XTANDI (enzalutamide), the life cycle management of TARCEVA (erlotinib), as well as pipeline compounds. Earlier in his career, he served in commercial strategic analysis and planning leadership roles centered on life cycle management, business development, and forecasting at Cephalon Oncology, Novartis Oncology, Bayer Oncology, and Pharmacia & Upjohn. He obtained his medical training at the University of Medicine and Pharmacy “Iuliu Hatieganu” in Cluj-Napoca, Romania, and his MBA at the University of South Carolina.
Leah DiMascio, PhD, PMP
Dr. DiMascio previously served as Senior Director, Project Management and Corporate Operations at ESSA Pharmaceuticals where she was instrumental in establishing the company’s Houston operations. Before ESSA, she was Senior Program Manager at Vermilllion, Inc. There, in addition to her program management responsibilities, she developed and implemented business planning processes and managed Vermillion’s relationships with all external collaborators and KOLs. Prior to Vermillion she held project management positions of increasing responsibility at Apocell and Emergent Biosolutions. Dr. DiMascio received her Ph.D. in Pharmacology and Cancer Biology from Duke University and her B.S. in Biology, Summa Cum Laude from Virginia Tech.